Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Immunogenicity and acceptance of influenza A (H1N1) vaccine in a cohort of chronic hepatitis C patients receiving pegylated-interferon treatment.

Hernández-Guerra M, González-Méndez Y, de Molina P, Gimeno-García AZ, Carrillo M, Casanova C, Pumarola T, Jimenez A, Hernández-Porto M, Torres A, Quintero E.

PLoS One. 2012;7(11):e48610. doi: 10.1371/journal.pone.0048610. Epub 2012 Nov 8.

2.

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.

Cullen G, Bader C, Korzenik JR, Sands BE.

Gut. 2012 Mar;61(3):385-91. doi: 10.1136/gutjnl-2011-300256. Epub 2011 Jul 13.

PMID:
21757451
3.

Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.

Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H.

Vaccine. 2012 Nov 6;30(48):6864-70. doi: 10.1016/j.vaccine.2012.09.005. Epub 2012 Sep 16.

PMID:
22989690
4.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.

PMID:
22475864
5.

Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.

Lertdumrongluk P, Changsirikulchai S, Limkunakul C, Prachukthum P, Punpiput P, Buppanharun R, Chotpitayasunondh C.

Vaccine. 2012 Feb 1;30(6):1108-14. doi: 10.1016/j.vaccine.2011.12.023. Epub 2011 Dec 15.

PMID:
22178515
6.

Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C.

Ohfuji S, Fukushima W, Tamori A, Maeda K, Maeda A, Hirota Y.

Influenza Other Respir Viruses. 2013 May;7(3):456-65. doi: 10.1111/j.1750-2659.2012.00424.x. Epub 2012 Aug 16.

7.

Response to a monovalent 2009 influenza A (H1N1) vaccine.

Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL.

N Engl J Med. 2009 Dec 17;361(25):2405-13. doi: 10.1056/NEJMoa0907413. Epub 2009 Sep 10.

8.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
9.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.

Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099. Epub 2011 Aug 2.

PMID:
21816199
10.

Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.

Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, Shen D, Wang JR, Sung JM.

Vaccine. 2012 Jul 13;30(33):5009-18. doi: 10.1016/j.vaccine.2012.05.016. Epub 2012 May 30.

PMID:
22658967
11.

Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.

Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.

Vaccine. 2011 Sep 16;29(40):6888-93. doi: 10.1016/j.vaccine.2011.07.050. Epub 2011 Jul 29.

PMID:
21803100
12.

Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.

Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn PM, McCullers JA.

Vaccine. 2012 Jan 20;30(5):879-85. doi: 10.1016/j.vaccine.2011.11.105. Epub 2011 Dec 9.

PMID:
22155630
13.

Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.

Maruszak H, Jeganathan S, Smith DE, Robertson P, Barnes T, Furner V.

HIV Med. 2012 Jul;13(6):352-7. doi: 10.1111/j.1468-1293.2011.00987.x. Epub 2012 Feb 2.

14.

Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.

Fairhead T, Hendren E, Tinckam K, Rose C, Sherlock CH, Shi L, Crowcroft NS, Gubbay JB, Landsberg D, Knoll G, Gill J, Kumar D.

Transpl Infect Dis. 2012 Dec;14(6):575-83. doi: 10.1111/tid.12006. Epub 2012 Sep 24.

PMID:
22999005
15.

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.

Vaccine. 2010 Feb 17;28(7):1740-5. doi: 10.1016/j.vaccine.2009.12.014. Epub 2009 Dec 22.

PMID:
20034605
16.

Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.

Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.

Vaccine. 2009 Aug 27;27(39):5357-62. doi: 10.1016/j.vaccine.2009.06.082. Epub 2009 Jul 14.

PMID:
19607951
17.

HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains.

Luytjes W, Enouf V, Schipper M, Gijzen K, Liu WM, van der Lubben M, Meijer A, van der Werf S, Soethout EC.

Vaccine. 2012 Jul 27;30(35):5262-9. doi: 10.1016/j.vaccine.2012.05.060. Epub 2012 Jun 9.

PMID:
22691431
18.

Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study.

Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, Guillevin L, Villiger PM.

Rheumatology (Oxford). 2012 Apr;51(4):695-700. doi: 10.1093/rheumatology/ker389. Epub 2011 Dec 14.

PMID:
22171015
19.

Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus.

Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Huong DB, Wechsler B, Hervier B, Miyara M, Morel N, Le Corre N, Arnaud L, Piette JC, Musset L, Autran B, Rozenberg F, Amoura Z.

Arthritis Rheum. 2011 Nov;63(11):3502-11. doi: 10.1002/art.30576.

20.

Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients.

Torii Y, Kimura H, Ochi N, Kaneko K, Ando H, Kiuchi T, Ito Y.

Vaccine. 2011 Jun 6;29(25):4187-9. doi: 10.1016/j.vaccine.2011.04.012. Epub 2011 Apr 20.

PMID:
21513762

Supplemental Content

Support Center